Next Article in Journal / Special Issue
Is Glioblastoma an Epigenetic Malignancy?
Previous Article in Journal
Dynamic Length Changes of Telomeres and Their Nuclear Organization in Chronic Myeloid Leukemia
Previous Article in Special Issue
Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment
Open AccessReview

Emerging Biomarkers in Glioblastoma

Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
Author to whom correspondence should be addressed.
Cancers 2013, 5(3), 1103-1119;
Received: 29 June 2013 / Revised: 14 August 2013 / Accepted: 19 August 2013 / Published: 22 August 2013
(This article belongs to the Special Issue Glioblastoma)
Glioblastoma, the most common primary brain tumor, has few available therapies providing significant improvement in survival. Molecular signatures associated with tumor aggressiveness as well as with disease progression and their relation to differences in signaling pathways implicated in gliomagenesis have recently been described. A number of biomarkers which have potential in diagnosis, prognosis and prediction of response to therapy have been identified and along with imaging modalities could contribute to the clinical management of GBM. Molecular biomarkers including O(6)-methlyguanine-DNA-methyltransferase (MGMT) promoter and deoxyribonucleic acid (DNA) methylation, loss of heterozygosity (LOH) of chromosomes 1p and 19q, loss of heterozygosity 10q, isocitrate dehydrogenase (IDH) mutations, epidermal growth factor receptor (EGFR), epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1 (ELTD1), vascular endothelial growth factor (VEGF), tumor suppressor protein p53, phosphatase and tensin homolog (PTEN), p16INK4a gene, cytochrome c oxidase (CcO), phospholipid metabolites, telomerase messenger expression (hTERT messenger ribonucleic acid [mRNA]), microRNAs (miRNAs), cancer stem cell markers and imaging modalities as potential biomarkers are discussed. Inclusion of emerging biomarkers in prospective clinical trials is warranted in an effort for more effective personalized therapy in the future. View Full-Text
Keywords: glioblastoma; molecular classification of glioblastoma; molecular biomarkers; imaging biomarkers glioblastoma; molecular classification of glioblastoma; molecular biomarkers; imaging biomarkers
Show Figures

Figure 1

MDPI and ACS Style

McNamara, M.G.; Sahebjam, S.; Mason, W.P. Emerging Biomarkers in Glioblastoma. Cancers 2013, 5, 1103-1119.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop